Fig. 1From: Concomitant Sjögren’s disease as a biomarker for treatment effectiveness in rheumatoid arthritis - results from the Swiss clinical quality management cohortFlow chart of eligible patients and treatment courses after each inclusion step. 1Patients with sicca symptoms but without Sjögren’s disease diagnosis were excluded (n = 2417). b/tsDMARD, biologic/ targeted synthetic disease-modifying anti-rheumatic drug; FU, follow-up; JAKi, Janus kinase-inhibitor; OMA, other modes of action; SCQM, Swiss Clinical Quality Management in Rheumatic Diseases; SjD, Sjögren’s disease; TC, treatment course; TNFi, Tumour necrosis factor-inhibitorBack to article page